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heparin-binding sites on the platelet surface and to define
how heparin influences platelet function through its direct
interactions with the platelet. When binding studies iden-
tified the platelet integrin αIIbβ3 as a putative heparin-
binding site, the ensuing physiologic investigations
focused on integrin function and signaling. Heparin-
mediated platelet aggregation was influenced by inhib-
itors, competitors, and calcium concentrations in a typical
integrin-dependent fashion. We found that pharmacologic
concentrations of heparin increased the binding of fi-
brinogen to activated platelets, whereas higher concentra-
tions did not. Finally, we observed that a low molecular
weight guanosine triphosphate–binding protein, Rap2B,
became incorporated into the activation-dependent
cytoskeleton during heparin-mediated aggregation.
METHODS
Reagents. The following materials were purchased:
porcine mucosal heparin (179 anti-Xa U/mg; MW
13,500) from Celsus Co (Cincinnati, Ohio); end point
attached heparin-agarose and concanavalin A–agarose
from Sigma Chemical Co (St Louis, Mo); tritiated
heparin, 0.55 mCi/mg, average MW 15,500 from NEN
Life Science Products, Inc (Boston, Mass); human
fibrinogen, thrombin (600 NIH U/mg protein); and the
remaining reagents from Sigma Chemical Co, or as
described below (General Biochemical Methods, online
only).
Platelet preparations and aggregometry. Platelet-
rich plasma (PRP) was prepared from fresh citrated blood
from drug-free volunteer donors (1:9, 3.8% trisodium cit-
A clearer understanding of the independent effects of
heparin on platelet function is essential to the safe use 
of heparin, especially considering the growing diversity of
heparins and their expanding indications in cardiovascular
disease. Yet, there remains significant controversy as to
precisely what are the effects of heparin on platelets and
their mechanisms. 
In characterizing the binding of pharmaceutical
heparin to human platelets, we demonstrated that heparin
bound to one high affinity site, with a dissociation con-
stant of about 200 nmol/L.1,2 Others have shown that
pharmaceutical heparin causes platelet aggregation and
activation, as measured in vitro with platelet aggregome-
try3,4 or in vivo with surface markers of activation.5,6 This
current investigation was intended to identify specific
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Purpose: Heparin binds to human platelets and can cause activation and aggregation, although the mechanisms are
unknown. To determine how heparin alters platelet function, we identified platelet-binding sites for heparin and mea-
sured heparin’s influence on the function of platelet integrin αIIbβ3 (glycoprotein IIb/IIIa). 
Methods: Photoaffinity cross-linking and affinity chromatography experiments were performed to identify platelet mem-
brane proteins that bind heparin. Heparin’s effect on fibrinogen binding to platelets was measured with a radioligand-
binding assay. The translocation to the cytoskeleton of Rap2, a guanosine triphosphate–binding protein, was measured
from platelets aggregating in response to heparin and other agonists.
Results: Cross-linking and affinity chromatographic experiments positively identified the integrin αIIbβ3 as a heparin-
binding site. Heparin aggregation was calcium dependent. Low concentrations of unfractionated porcine mucosal
heparin (2-5 U/mL) significantly increased fibrinogen I 125 binding to activated platelets, whereas higher doses did
not. Heparin-mediated platelet aggregation was completely blocked by GRGDS peptide (5 mmol/L), a competitive
inhibitor of fibrinogen binding, and was blocked by EDTA (2 mmol/L), which dissociates the functional integrin com-
plex. Aggregation was associated with Rap2 translocation to the cytoskeleton, a sign of outside-in signaling. 
Conclusions: Heparin binds to the αIIbβ3 integrin in vitro and ex vivo, and heparin increases fibrinogen binding to the
integrin. Heparin-mediated aggregation requires an intact integrin and ligand and leads to Rap2 translocation to the
cytoskeleton—an outside-in signal of ligand engagement. Heparin may directly modulate platelet integrin function,
most likely through direct binding and modulation of integrin function. (J Vasc Surg 2001;33:587-94.)
rate, vol/vol), who gave consent according to an approved
protocol by the Institutional Review Board. PRP was used
directly in some experiments. In other experiments, the
platelets were separated in the presence of apyrase (0.1
U/mL) by washing (with our modification2 of the
method of Suzuki7), or by gel filtration,8 and were resus-
pended in Tyrode’s HEPES buffer (137 mmol/L NaCl,
2.7 mmol/L KCl, 0.42 mmol/L NaH2PO4, 12.5
mmol/L NaHCO3, 5.6 mmol/L dextrose, 10 mmol/L
HEPES, 0.2% ovalbumin, and 0.1 mg/mL fibrinogen at
pH 7.4). Specifically stated dilutions of calcium chloride
were added to the buffer before testing. Platelet aggrega-
tion was measured turbidmetrically in a Scienco dual chan-
nel aggregometer (Morrison, Colo),9 with an expanded
scale for heparin aggregations, as described by Salzman et
al.3 Siliconized glass cuvettes were filled with 180 µL of
platelet mixture, to which typically 20 µL of additive or
agonist was added, to achieve the desired final concentra-
tions as described. Platelets were counted with a Coulter
counter, and final counts were adjusted to approximately
200,000 per microliter. 
For analysis of Rap2, after 5 minutes of spinning in the
aggregometer in response to agonist (or buffer control),
the platelets were rapidly spun through buffer with 5
mmol/L EDTA. The platelet proteins were then extracted
in 100 µL of platelet lysis buffer: 10 mmol/L sodium
phosphate (pH 7.4), 0.15 mol/L NaCl, 1% (vol/vol)
Triton X-100 (reduced; Fluka, Milwaukee, Wis), antipain
(50 µmol/L), chymostatin (50 µmol/L), E-64 (5
µmol/L), leupeptin (50 µmol/L), pepstatin A (1
µmol/L), Pefabloc SC Plus (2 mmol/L; Roche Molecular
Biochemicals, Indianapolis, Ind), EGTA and EDTA (both
at 10 mmol/L), and sodium orthovanadate (3 mmol/L).
Before analysis, the detergent-insoluble cytoskeleton (pel-
let) was separated from the detergent-soluble platelet pro-
teins (supernatant) by centrifugation at 13,000g for 20
minutes at 4°C. The supernatant was saved, and the pellet
was washed once with 1 mL of platelet lysis buffer con-
taining all additions. For sodium dodecylsulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE), the samples were
prepared in Laemmli-reducing buffer containing 100
mmol/L dithiothreitol, and equal amounts of protein
were applied to each lane, as represented by equal num-
bers of platelets.
Photoaffinity cross-linking. The heterobifunctional,
photoactivatable cross-linking reagent, AA-D, covalently
bonds to carbohydrates through their hydroxyl groups,
without significant alteration of their biological activity.10
Its application has been previously described in detail.11
Tritiated heparin (1.5 mg) was first labeled with 0.6 mg of
AA-D, and the labeled product was separated with G-25
Sephadex column chromatography (Fig 1). Then, AA-
D–tritiated heparin, 0.25 mg/mL, was incubated with
fresh, washed human platelets suspended in Hank’s bal-
anced salt solution, at a final concentration of approxi-
mately 1 × 106 cells per microliter. After 5 minutes of
preincubation, the platelet/AA-D–tritiated heparin mix-
ture was photoirradiated with UV light at 254 nm for 15
minutes with gentle stirring. Identical control mixtures
were incubated but not exposed to UV light, and subse-
quently processed in the same manner, as previously
described.11
Fibrinogen-platelet binding assay. Human fibrin-
ogen (Sigma Chemical Co) was radioiodinated as previ-
ously described12 to an estimated specific activity of 
5.9 Ci/g. Gel-filtered platelets (100,000 cells per 
µL, final concentration) were activated with 1 U/mL 
of thrombin (Sigma Chemical Co, 600 NIH U/mg 
protein) and different concentrations of heparin (0-50
USP units/mL), in the presence of 1 mmol/L of calcium
chloride. After platelet activation, thrombin was neutral-
ized by an excess of hirudin, and the platelets were incu-
bated with fibrinogen I 125 (10–10 mol/L final
concentration) for 30 minutes at 37°C. Nonspecific bind-
ing was assessed with parallel incubations in the absence of
thrombin and heparin. After equilibrium, the binding
reaction was stopped by the addition of 400 µL of cold
(4°C) assay buffer and centrifuged at 15,000g (10 min-
utes, 4°C). The supernatant fraction was aspirated and the
iodine 125 content of the pellet was measured with a
gamma counter.
Statistical analysis. All values were reported as the
mean ± SE of the mean. Analysis was performed with
Sigmastat software (Jandel Scientific, San Rafael, Calif).
Individual experiments were performed in duplicate,
and the values were averaged. The aggregate data from
three to seven separate experiments were used for statis-
tical analysis of fibrinogen binding, with the use of one-
way repeated-measures of analysis of variance followed
by the Dunnett test to evaluate the effects of different
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Fig 1. AA-D–tritiated heparin, the heterobifunctional cross-linking
reagent used to identify heparin-binding proteins on the platelet
surface.
concentrations of heparin, compared with controls (no
heparin). Significance was taken at the level of P less
than .05.
RESULTS
Heparin binds to platelet integrin αIIbβ3. Initial
experiments were performed to determine which platelet sur-
face glycoproteins might bind heparin. A Triton-solubilized
membrane fraction was first extracted with concanavalin A to
isolate platelet surface glycoproteins.13,14 In Fig 2, lanes 2
and 4 illustrate the range of proteins in the original platelet
membrane extract and the plentiful glycoproteins yielded by
concanavalin A selection. Both of these samples contained a
high concentration of the β3 integrin, glycoprotein IIIa, as
demonstrated by immunostaining of their corresponding
Western blots (Fig 2, lanes 3 and 5). The postconcanavalin A
fraction (enriched with platelet membrane glycoproteins) was
then subjected to heparin affinity chromatography. A single
protein peak with high affinity for heparin eluted at a molar-
ity of 0.5 to 0.6 mol/L NaCl. The nonbinding (flow-
through) and high affinity fractions were pooled separately,
desalted, and analyzed by 12% reduced SDS-PAGE. Fig 2,
lanes 6 through 9 show that the β3 integrin was absent in the
nonbinding flow-through fraction, yet was enriched in the
protein peak with high affinity for heparin. The same pattern
of heparin affinity for the integrin αIIbβ3 was observed even
when the sequence of the separations was reversed (ie,
heparin affinity chromatography first, concanavalin A separa-
tion second); immunoreactive β3 was found in the heparin
high-affinity fraction (data not shown). Other major bands of
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 3 Sobel et al 589
heparin-binding proteins were also observed, most notably at
130 to 140 kD (probably αIIb) and at 30 kD (unknown).
To confirm that heparin binds to the integrin αIIbβ3
when the receptor is expressed in its native conformation
on the platelet surface, we affinity cross-linked tritiated
heparin to fresh, washed intact platelets. Fig 3 shows that
heparin was predominantly cross-linked to theαIIbβ3 inte-
grin proteins. Autoradiography of the transblot of the
cross-linked platelet proteins visualized significant bands
in the range of 250 to 300 kD (unknown protein), 130 to
140 kD (the MW of theαIIb integrin), 110 to 115 kD (the
MW of the β3 integrin), as well as labeled material below
44 kD. Immunostaining of the same membrane showed
that the two radioactive cross-linked protein bands at 130
to 140 and 110 to 115 kD were indeed the integrin het-
erodimer αIIbβ3. In fact, cross-linking of these proteins by
the AA-D–tritiated heparin interfered somewhat with their
subsequent recognition by monoclonal antibodies, further
suggesting that the radiolabeled proteins are identical to
the integrin proteins recognized by the monoclonal anti-
bodies. In the control experimental samples that were not
exposed to UV light (and were ostensibly not cross-
linked), no radioactive protein bands were visualized, and
the staining with the monoclonal antibodies was denser.
Heparin-mediated platelet aggregation. Platelet
aggregation was measured in both PRP and washed
platelets, in response to heparin (1-2 U/mL final concen-
tration) or the same volume of phosphate-buffered saline
(PBS) control. Among a wide range of normal donors 
(n = 10), aggregation (of 20% or more) was routinely
Fig 2. Analysis of platelet membrane proteins that bind heparin. Twelve percent reduced SDS-PAGE: (1) low molecular weight stan-
dards; (2) original platelet membrane extract; (3) immunostain for β3 of (2); (4) concanavalin A high affinity fraction; (5) immunostain
for β3 of (4); (6) heparin agarose nonbinding fraction; (7) immunostain for β3 of (6); (8) heparin high-affinity fraction; (9) immuno-
stain for β3 of (8); (10) high molecular weight standards.
observed in response to heparin, whereas no aggregation
responses at all were observed to control (PBS). To deter-
mine if the αIIbβ3 integrin was necessary for this aggrega-
tion response, we preincubated platelet samples with
inhibitors of integrin function. Fig 4 illustrates that EDTA
(2 mmol/L) or GRGDS peptide (5 mmol/L) completely
abolished heparin-mediated aggregation. These findings
were observed in all experiments (4/4).
Because integrin function depends, in part, on the
concentrations of extracellular divalent cations, we wanted
to see if heparin-mediated aggregation was also dependent
on the extracellular concentration of calcium. Samples of
washed platelets were resuspended in Tyrode’s HEPES
buffer (with fibrinogen, see “Methods” section) and sup-
plemented with a final concentration of 0 to 2 mmol/L
calcium chloride; the aggregation was measured in
response to 1 U/mL of heparin. Fig 5 shows that heparin-
mediated aggregation was most pronounced at low con-
centrations of extracellular calcium and was suppressed at
higher concentrations. Similar experiments were per-
formed in plasma by preparing blood in anticoagulants
that either do or do not chelate calcium to be sure this was
not an artifact of either the buffer system or washing.
Paired samples of PRP were prepared from the same
donor, with fresh whole blood that was anticoagulated
with citrate (a chelator of calcium, 0.38% final concentra-
tion) or PPACK (D-phenylalanyl-L-prolyl-L-arginyl
chloromethyl ketone, 60 µmol/L), a thrombin inhibitor
that does not alter plasma calcium. Heparin-mediated
aggregation was absent in PPACK PRP, but present in cit-
rated PRP (Fig 5). As expected, mixtures of citrated and
PPACK PRP showed intermediate responses to heparin. A
similar calcium dependency was noted in response to 5
µmol/L adenosine diphosphate (ADP); aggregation
responses of PPACK PRP were muted compared with
those in citrated PRP (data not shown).
Heparin modulation of fibrinogen binding to
platelets. Because fibrinogen is the primary ligand for this
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Fig 3. Photoaffinity cross-linking of heparin to intact platelets. Samples of fresh, washed platelets were incubated with AA-D–tritiated
heparin cross-linker, and then exposed to UV light (or not), and the cross-linked platelets washed and solubilized. A, Coomassie stain
of original 6% SDS-PAGE of platelet proteins after electrotransfer (with MW standards in kD). B, Autoradiography of the same lanes
from the Western blot. C, Immunostaining of same blot for αIIbβ3. GP, Glycoprotein.
Fig 4. Inhibition of heparin-mediated platelet aggregation.
Citrated PRP was preincubated with GRGDS peptide or EDTA
or saline control, and then exposed to heparin 1 U/mL final con-
centration. This illustrates similar results of four experiments.
A B C
receptor, we performed radioligand-binding experiments
to determine precisely how heparin influenced the binding
of fibrinogen in resting and stimulated platelets.
Unstimulated platelets bound negligible quantities of fi-
brinogen, but low concentrations of heparin appeared to
increase fibrinogen binding slightly, although not statisti-
cally significantly. However, heparin’s effect was more sig-
nificant in activated platelets. Fig 6 shows that activated
platelets exposed to 2 or 5 U/mL heparin bound signifi-
cantly more fibrinogen than those exposed to no heparin
(P < .05, analysis of variance). Higher concentrations of
heparin (up to 50 U/mL) showed no enhancement of
thrombin-induced fibrinogen-binding, compared with
that binding observed without heparin. 
Association of Rap2 with the cytoskeleton. In
unstimulated platelets, Rap2B was found in association
with the supernatant fraction, as would be expected.
Thrombin-induced aggregation produced a large translo-
cation of Rap2B to the cytoskeletal-containing fraction.
Aggregation in response to ADP or heparin produced
lesser degrees of Rap2B translocation to the cytoskeleton,
but more than seen in control samples (data not shown).
Fig 7 presents a composite of the platelet aggregatory
responses to heparin (1 U/mL) compared with PBS (con-
trol). The corresponding analysis of detergent-insoluble
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cytoskeletal fractions from these samples shows the pres-
ence of Rap2 in the heparin-aggregated sample, but neg-
ligible Rap2 detectable in the control platelets. 
DISCUSSION
The phenomenon of heparin-mediated platelet aggre-
gation and activation has been known for many years.
Michalski et al4 and Salzman et al3 demonstrated that low,
pharmacologic concentrations of heparin induced mild
aggregation of citrated PRP and augmented the aggrega-
tions induced by ADP. Dunn et al15 showed that heparin
enhanced the binding of fibrinogen to ADP-stimulated
platelets by 11% to 30%, but they only examined low con-
centrations of heparin. Later, Chong and others found
that heparin’s proaggregatory effects (1) required platelet
metabolic energy, (2) were unaffected by inhibitors of
prostaglandin synthesis, and (3) did not depend on ADP
or von Willebrand factor.16,17 Storck et al5 showed that
heparin increased the surface expression of glycoprotein
IIb/IIIa (αIIbβ3) in resting or ADP-stimulated platelets.
Xiao and Theroux6 recently reported a nearly twofold
increase in surface markers for platelet activation in
patients receiving intravenous heparin, indicating the
potential clinical relevance of this effect. 
In this current study we have attempted to explain
Fig 5. Calcium dependence of heparin-mediated aggregation. Left panel: Washed platelets were reconstituted with fibrinogen and a range
of extracellular calcium concentrations, and aggregation to heparin measured (see “Methods” section for details). Labels indicate the 
final concentration of supplemental calcium chloride that was added to buffer. Right panel: Calcium dependence of heparin-mediated
aggregation in PRP. PRP was prepared from blood anticoagulated with PPACK or citrate at indicated final concentrations, and aggrega-
tion to heparin measured (see “Methods” and “Results” sections for details). CaCl2, Calcium chloride. 
how heparin might exert these effects—where does it
bind, what pathways does it influence? This current work
reveals that heparin binds to the platelet integrin, αIIbβ3.
Cross-linking experiments show that heparin binds
directly to the αIIbβ3 integrin on intact, live platelets. The
physiology of heparin-mediated platelet aggregation bears
many characteristics of an integrin-dependent process:
blockade or disruption of the integrin’s function abrogates
heparin-mediated aggregation. Also, heparin-mediated
aggregation is influenced by the extracellular concentra-
tion of calcium in a typical integrin-dependent manner.
Fibrinogen binding to the platelet is enhanced in the pres-
ence of pharmacologic concentrations of heparin, but not
so at higher, suprapharmacologic levels. Finally, heparin-
mediated aggregation induced Rap2 translocation to the
cytoskeleton, which is a marker of integrin-ligand engage-
ment and outside-in signaling. 
Heparin binds to a myriad of different proteins, many
of which are associated with the platelet: growth factors,
adhesive proteins, and secreted platelet-specific proteins
like platelet-factor 4. Our current methods of membrane
preparation, affinity chromatography, and cross-linking
have been designed to effectively exclude heparin interac-
tions with all but firmly attached membrane proteins.
These results showed that αIIbβ3 binds heparin. The
results of the photoaffinity cross-linking experiments are
most conclusive: the predominant cross-linked proteins on
the platelet surface were αIIbβ3. Several other heparin-
binding platelet surface proteins were also visualized, most
notably an approximately 30-kD protein. We are actively
pursuing the identity of these other proteins. 
Integrin function is calcium sensitive. Salt bridges and
divalent cations are essential for the functional assembly of
the two integrin subunits.18,19 Divalent cations may induce
a conformational change in the integrin,20 or they may
bridge the acidic RGDS domains of the ligand to the
receptor.18 For the platelet αIIbβ3, chelation of Ca2+ with
EDTA completely dissociates the heterodimers. Within the
physiologic range, higher extracellular Ca2+ generally stabi-
lizes the platelet in a low-affinity state, whereas low levels
of extracellular Ca2+ favor a high-affinity state. In the cur-
rent experiments, the responses of heparin-mediated
aggregation follow the pattern expected for the αIIbβ3 inte-
grin. When no exogenous calcium is added to the buffer
system, aggregation is still supported, probably by the
small residual amounts of calcium found in the buffers and
that released by the platelets. When the calcium concentra-
tion is raised, aggregation responses to heparin are
reduced. In parallel aggregation experiments, we observed
the same response to the agonist ADP as was observed for
heparin: a muted aggregation response at the higher Ca2+
concentrations in PPACK anticoagulated blood. The cal-
cium experiments thus lend further credence that heparin-
mediated aggregation is an integrin-dependent process. 
Heparin increased fibrinogen binding to the platelet.
This was most significant in the activated platelet, but the
trend was borne out even in the resting platelet. The con-
centration dependence of heparin’s effect certainly sug-
gests a specificity for the interaction: low concentrations of
heparin significantly enhanced binding, whereas 50
U/mL had no effect. This observation is supported by the
report of Rohrer et al21 who observed that extremely high
heparin concentrations inhibited α granule release. At
high concentrations, the shear mass effect of heparin’s
high charge density may actually blunt normal platelet
activation mechanisms, or heparin may compete with
fibrinogen binding. 
The Rap proteins are members of the Ras superfamily.
Rap1 and Rap2 are 60% homologous, and the B variants are
abundant in platelets. In nucleated cells, Rap 1B and 2B
may play a role in modulating the downstream effectors of
Ras,22,23 but their precise function in platelets is unknown.
However, during platelet activation and aggregation, Rap is
known to rapidly associate with the activation-dependent
cytoskeleton in a calcium-dependent fashion.24 The appear-
ance of Rap in the detergent-insoluble cytoskeletal fraction
is driven by the secondary signals generated by platelet
aggregation. Outside-in signaling of the integrin (ie, inter-
nal signals generated by fibrinogen binding and aggrega-
tion) was thought to be a specific prerequisite for Rap
translocation,25 but recent studies suggest that outside-in
signaling by von Willebrand factor binding to glycoprotein
Ib can also induce Rap translocation.26 In the current inves-
tigation of heparin-mediated platelet aggregation, Rap2B
translocation serves as a useful marker for the early signal-
ing events associated with activation-dependent cytoskeletal
reorganization. This is most likely integrin mediated,
because it is already known that heparin aggregation does
not require von Willebrand factor.
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Fig 6. Fibrinogen I 125 binding to inactivated and thrombin-
activated platelets was measured over a range of heparin concen-
trations. At concentrations of 2 and 5 U/mL heparin, fibrinogen
binding was significantly increased. The results are means ± SEM
of 4 to 7 independent experiments.
This current study has not addressed two important
aspects of heparin-platelet interactions that have been
more thoroughly investigated elsewhere: (1) the syn-
drome of immune-mediated, heparin-induced thrombocy-
topenia and thrombosis27 and (2) heparin’s inhibition of
von Willebrand factor hemostatic function.12,28,29 In both
of those cases, the effects of heparin on platelet function
are indirect, either through the action of acquired anti-
bodies, or by heparin binding to the plasma protein von
Willebrand factor. 
These current data have provided new insights into
the physiology and mechanisms of heparin’s stimulation
and activation of human platelets. Heparin binds to the
integrin receptor αIIbβ3. Heparin-mediated platelet aggre-
gation requires an intact, functional integrin and is depen-
dent on the extracellular concentration of calcium. Low
pharmacologic concentrations of heparin enhance fibrino-
gen binding. Heparin-mediated aggregation is accompa-
nied by a hallmark of outside-in platelet signaling, the
translocation of Rap2B to the cytoskeleton. 
Several mechanisms for heparin’s agonist activity are
possible. First, heparin binding to the integrin may
directly modulate the conformation of the heterodimer,
favoring or stabilizing it in a higher affinity state, or
heparin binding to the integrin may alter the local ionic
environment of the integrin so as to alter the affinity of the
ligand-binding pocket. Given the important influence of
the local extracellular ionic environment (eg, the sensitiv-
ity of integrin function to divalent cations), it is possible
that the anionic heparin molecule may also modulate inte-
grin conformation and signal transduction, perhaps
through binding interactions at calcium sensitive sites. It is
also possible that a direct interaction between heparin and
fibrinogen somehow enhances fibrinogen’s affinity for its
receptor, αIIbβ3.
Rather than directly modulating the binding of fibrino-
gen to the integrin αIIbβ3, heparin could act as an inde-
pendent platelet agonist through an as yet unidentified
receptor. In such a case, heparin’s observed enhancement
of the affinity of αIIbβ3 would result from the additive
effects of agonists. However, this alternative explanation
does not account for heparin’s binding to αIIbβ3, nor has a
distinct heparin “receptor” been identified. 
The clinical significance of this nonimmune-mediated
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stimulation of platelets by heparin is certainly a more sub-
tle problem than heparin-induced thrombocytopenia and
thrombosis. However, this milder stimulation of platelets
by heparin can likely be observed in most patients, if sen-
sitive enough detection methods are used. For arterial
surgery and extracorporeal circulation, an ideal heparin
should have no platelet effects, or even better, should be
designed to have platelet inhibitory effects, as we have pre-
viously shown is possible.29 A better understanding of
where and how heparin exerts its cellular effects may offer
several avenues for future clinical relevance. First, it will
aid in the development and structural design of heparins
with more specific, focused biological activities, and with
fewer undesirable effects. Second, the insights gained from
the study of heparin-platelet interactions may be relevant
to heparin interactions with other vascular cells. 
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GENERAL BIOCHEMICAL METHODS
Platelet membrane extracts were prepared from freshly
expired platelet concentrates with the glycerol lysis tech-
nique1 in the presence of protease inhibitors. For affinity
chromatography, this membrane fraction was solubilized in
1% Triton X-100 in Tris-buffered saline (TBS) (0.1 mol/L
NaCl, 0.05 mol/L Tris, pH 7.3). The detergent soluble
platelet membranes were applied in 0.1% Triton with TBS
in batch fashion to the chosen affinity matrix. The mixture
was then poured into a conventional chromatography col-
umn for separation. The protein effluent was monitored by
absorption at 280 nm, and the column copiously washed
until no more protein eluted. Then, the high affinity 
fractions were eluted in 0.1% Triton, 0.2 mol/L phosphate-
buffered saline, pH 7.0, with a 0.15 to 2.0 mol/L. NaC1
gradient in 0.1% Triton, with TBS (for heparin agarose), 
or with α-methyl mannoside 0.5 mol/L (for concanava-
lin A agarose). Protein fractions were quantified with 
a protein assay and analyzed with sodium dodecylsulfate-
polyacrylamide gel electrophoresis (6%), according to
Laemmli.2 After electrophoresis, the gel was equilibrated in
transfer buffer, and the proteins were transferred to a
polyvinylidene difluoride membrane (Immobilon-P;
Millipore Corp, Bedford, Mass) with a Janssen semi-dry
blotting apparatus. From these membranes, imaging of
radiolabeled heparin was accomplished with BAS-3000 and
BAS-2000 systems (Fuji Photo Film, Tokyo, Japan).
For Western blotting, the membrane was washed
briefly in water and then blocked for 1 hour with agitation
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in SuperBlock for Blotting-PBS (Pierce Chemical Co,
Rockford, Ill) at room temperature. All primary, sec-
ondary, and tertiary probes were suspended in SuperBlock
containing 0.05% (vol/vol) Tween20 (SurfactAmp;
Pierce) and incubated at room temperature for 1 hour. For
the integrin αIIbβ3, transblots were probed with either an
anti–glycoprotein IIb (anti-αIIb integrin) antibody
(Immunotech, Inc, Miami, Fla), or anti-β3 mAb 7G2,3 or
both together. For Rap2, they were probed with mAb
R23020 (BD Biosciences–Transduction Laboratories,
Lexington, Ky). After copious washing, membranes were
probed with the secondary antibody, biotinylated goat anti-
mouse immunoglobulin G (1:100,000 dilution); washed;
probed with a streptavidin-biotinylated-horseradish peroxi-
dase complex (1:50,000; Amersham Pharmacia Biotech,
Inc, Piscataway, NJ); washed; and finally visualized with a
chemiluminescence system (Pierce SuperSignal Dura chemi-
luminescence substrate) as per the manufacturer’s instruc-
tions. Light-emitting bands were detected on blue-sensitive
x-ray film (Pierce).
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